US judge orders probe of Novartis $30 mln settlement claims process
By Brendan Pierson
June 6 (Reuters) -A federal judge has ordered a probe of the claims distribution process in a $30 million settlement by Novartis NOVN.S with consumers and health plans in an antitrust class action over its hypertension drug Exforge, citing concerns about its integrity.
U.S. District Judge Alvin Hellerstein in Manhattan in an order on Wednesday said that of more than 132,000 consumer claims submitted to the settlement administrator, just over 22,000 were allowed, which "seems disproportionately low."
Of the checks mailed to consumers whose claims were deemed eligible,nearly 15,000, totaling about $2.1 million, have become stale for failure to be deposited, Hellerstein said.
That is out of about $4.8 million of the $30 million that was set aside for consumers. The rest of the settlement went to third-party payors like health plans and insurance companies and to legal fees and costs.
"An inquiry by the court is required to assure the integrity of the claims distribution process," Hellerstein wrote.
He appointed U.S. Magistrate Judge Stewart Aaron to oversee that inquiry and prepare a report on his findings. Lawyers for plaintiffs and Novartis did not immediately respond to requests for comment.
Hellerstein's order comes amid growing concern that class action settlements can be targeted by scammers. More than 80 million claims submitted to class action settlement funds in 2023 showed "significant" signs of fraud, up more than 19,000% since 2021, according to a report last month from digital payment processor Digital Disbursements.
The consumers and third-party payors had accused Basel, Switzerland-based Novartis of violating federal antitrust law by entering into an illegal "reverse payment" agreement with Endo International's EO7.F Par Pharmaceutical unit to delay launches of less expensive, generic versions of Exforge, which treats hypertension to lower blood pressure and reduce the risk of strokes.
They said Par agreed not to launch a generic Exforge product for two years after the expiration of one of Novartis's patents, and Novartis agreed not to compete with Par by launching its own Exforge generic during the 180-day exclusivity period Par enjoyed as the first generic on the market.
The $30 million is part of a broader $245 million settlement that Novartis reached in 2022, which also includes claims by drug wholesalers and retailers.
Novartis's annual U.S. sales of brand-name Exforge exceeded $400 million before generic versions were sold.
The case is In re Novartis and Par Antitrust Litigation, U.S. District Court, Southern District of New York, No. 18-04361.
For Novartis: Evan Chesler of Cravath, Swaine & Moore
For plaintiffs: Gregory Asciolla of DiCello Levitt and Robert Eisler of Grant & Eisenhofer
Read more:
Novartis to pay $30 mln to health plans, consumers over Exforge antitrust claims
Novartis to pay $245 mln to end antitrust cases over Exforge drug generics
Reporting By Brendan Pierson in New York; editing by Nate Raymond
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
